Comparative Pharmacology
Head-to-head clinical analysis: QVAR REDIHALER versus SYMBICORT AEROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QVAR REDIHALER versus SYMBICORT AEROSPHERE.
QVAR REDIHALER vs SYMBICORT AEROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beclomethasone dipropionate is a prodrug that is hydrolyzed by esterases to the active metabolite beclomethasone-17-monopropionate (17-BMP). 17-BMP is a glucocorticoid receptor agonist that binds to the glucocorticoid receptor, leading to modulation of gene expression involved in inflammatory pathways, including inhibition of pro-inflammatory cytokines, reduction of eosinophil survival and migration, and suppression of mast cell mediators.
Budesonide is a corticosteroid with anti-inflammatory activity; its mechanism includes inhibition of multiple inflammatory cell types and mediators. Formoterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation: 40-80 mcg twice daily; maximum 320 mcg twice daily.
Two inhalations (budesonide 160 mcg/formoterol 4.5 mcg per inhalation) twice daily (morning and evening). Maximum dose: 2 inhalations twice daily.
None Documented
None Documented
1.5-2.0 hours (terminal half-life) after inhalation; supports twice-daily dosing.
Budesonide: 2-3 hours. Formoterol: 10-14 hours. Clinically, twice-daily dosing maintains effect due to active metabolite accumulation.
Primarily hepatic metabolism via CYP3A4; metabolites are excreted in feces (~64%) and urine (~12%).
Budesonide: 60% renal metabolites, 40% fecal. Formoterol: 60% renal, 40% fecal via biliary, with 10% unchanged drug.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-Acting Beta Agonist